Bempedoic acid is a cholesterol-lowering medication that works in the liver to reduce LDL (“bad”) cholesterol. Sold under the brand name Nexletol, it’s taken as a single 180 mg tablet once daily, with or without food. It was designed primarily for people who can’t tolerate statins, and it represents the first new class of oral cholesterol-lowering drug in decades.
How It Lowers Cholesterol
Bempedoic acid is a prodrug, meaning it’s inactive when you swallow it. It only switches on after reaching the liver, where a specific enzyme converts it into its active form. Once activated, it blocks an enzyme called ATP citrate lyase, which sits upstream of the same cholesterol-production pathway that statins target. By shutting down this step, the drug reduces the amount of cholesterol the liver manufactures on its own.
When liver cells sense that their internal cholesterol supply has dropped, they respond by pulling more LDL cholesterol out of the bloodstream. They do this by producing more LDL receptors on their surface, essentially vacuuming up circulating LDL particles. The net result is lower LDL levels in your blood. In the large CLEAR Outcomes trial, bempedoic acid reduced LDL cholesterol by 21% compared to placebo over six months.
Why It’s Easier on Muscles Than Statins
Muscle pain is the most common reason people stop taking statins. Statins are active throughout the body, including in muscle tissue, which is thought to contribute to soreness, weakness, and cramping in some patients. Bempedoic acid sidesteps this problem because the enzyme needed to activate it exists almost exclusively in the liver. Since the drug never “turns on” in muscle cells, it doesn’t interfere with energy production in those tissues the way statins can.
This liver-specific activation is the core reason bempedoic acid was developed and why its primary audience is people with statin intolerance. In clinical trials, statin intolerance was defined as the inability to tolerate at least two different statins, including one at a low dose, due to side effects that appeared during treatment and went away after stopping.
Cardiovascular Benefits
Lowering LDL cholesterol matters because it reduces the risk of heart attacks and strokes, but not every cholesterol drug has been proven to deliver those outcomes in a clinical trial. Bempedoic acid has. The CLEAR Outcomes trial followed patients for a median of 3.4 years and measured a composite of four major cardiovascular events: death from heart disease, nonfatal heart attack, nonfatal stroke, and the need for a procedure to reopen blocked coronary arteries.
Among patients with diabetes, bempedoic acid reduced the risk of these combined events by 17% compared to placebo, translating to an absolute risk reduction of 2.4%. That means for roughly every 42 patients treated, one major cardiovascular event was prevented. These results are particularly meaningful because they came from a population that couldn’t take statins, a group that previously had limited options for proven heart protection.
FDA-Approved Uses
Bempedoic acid is approved for two purposes. First, as an add-on to diet and exercise for lowering LDL cholesterol in adults with high cholesterol, including a genetic form called heterozygous familial hypercholesterolemia. Second, it’s approved to reduce the risk of major cardiovascular events in adults who are at elevated risk but unable to take recommended statin therapy.
It’s also available in a combination tablet with ezetimibe (another cholesterol-lowering drug that works in the gut) under the brand name Nexlizet. This combination attacks cholesterol from two directions: reducing production in the liver and reducing absorption in the intestine.
Side Effects to Know About
The most notable side effect is a rise in uric acid levels, which can trigger gout in susceptible people. In the CLEAR Outcomes trial, gout occurred in 3.1% of patients taking bempedoic acid compared to 2.1% on placebo. The risk was higher for people who already had elevated uric acid at the start of the study: 7.7% experienced gout on bempedoic acid versus 5.2% on placebo. For those who were already taking medications to keep uric acid levels down, the difference between drug and placebo was smaller, suggesting that monitoring and treating elevated uric acid can help manage this risk.
Other reported side effects include upper respiratory infections, muscle spasms, and elevated liver enzymes. Tendon rupture is listed as a warning in the prescribing information, though it occurred rarely in trials. If you have a history of gout or tendon problems, these are worth discussing before starting treatment.
Interactions With Other Medications
Some people take bempedoic acid alongside a low-dose statin rather than as a full replacement. In those cases, dose limits apply to certain statins. Simvastatin should not exceed 20 mg daily, and pravastatin should not exceed 40 mg daily when used together with bempedoic acid. These limits exist because bempedoic acid can increase the blood levels of these particular statins, raising the chance of side effects.
Who It’s Designed For
Bempedoic acid fills a specific gap. If you’ve tried at least two statins and couldn’t tolerate them, including one at the lowest available dose, you fit the clinical definition of statin intolerance that guided the drug’s development and testing. Low doses in this context mean rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, or their equivalents.
It’s also used by people who are already on a statin but haven’t reached their LDL target and need additional lowering. A 21% reduction is modest compared to high-intensity statins, which can cut LDL by 50% or more, so bempedoic acid is not typically a first-line treatment for people who can tolerate statins comfortably. Its value lies in offering a proven, oral, once-daily option for patients who otherwise have few choices beyond injectable medications.